Kotak Mahindra Capital Company Ltd has submitted to the Exchange a copy of Pre-offer advertisement in accordance with Regulation 18(7) of the securities and exchange Board of India (SAST) Regulations, 2011, as amended, and corrigendum to the public announcement and detailed public statement for the attention of the public shareholders of the company.
HCG · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.7 pts less than Nifty Microcap 250 and 1.3 pts less than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Kotak Mahindra Capital has filed a pre-offer advertisement and corrigendum to the earlier public announcement for an open offer to buy up to 3.70 crore equity shares (26% of expanded voting share capital) of Healthcare Global Enterprises (HCG) from public shareholders. The offer is by KKR-backed Hector Asia Holdings II Pte. Ltd., along with persons acting in concert, at a price of ₹504.41 per share, with no revision from the original announcement. The acquirer has already completed the first tranche purchase of 50.43% stake from the seller (Aceso Company Pte. Ltd.) on May 30, 2025, and all regulatory approvals including from the Competition Commission of India and Competition Authority of Kenya have been received. The Independent Directors Committee has recommended the offer as fair and reasonable, noting the 60-day volume-weighted average price matches the offer price. The tendering window runs from July 21 to August 1, 2025, and the offer is not subject to any minimum acceptance condition.
Public shareholders can tender shares at ₹504.41 between July 21 and August 1, 2025, or hold the stock for potential long-term value under KKR ownership. The stock is likely to trade around the offer price, and shareholders should weigh the certainty of the cash exit versus staying invested in a private equity-controlled company.